Boehringer Ingelheim has pledged to invest a total of 11 billion euros in its new R&D programme over the next five years, 5 billion euros of which will go to preclinical research.
Some 1.5 billion euros of the total will be allocated to collaborations with external partners, the German family-run group noted. Michel Pairet, head of research and non-clinical development at Boehringer, said the new strategy “embraces the trend towards more extensive open-innovation approaches between academia and industry in biomedical research [and] our partners benefit by accessing our broad experience and capabilities and through establishment of long-term personal interactions with our R&D teams”.
He added that the new strategy “will foster our external collaboration efforts by enabling us to be faster and more flexible. This is of essence for research beyond the borders of our current focus areas, where we explore emerging science, new indications and new technology to expand opportunities”.
Meantime, Boehringer has just announced new collaborations with four partners focusing on inflammatory bowel disease, namely with the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine.